Wanjia CSI Hong Kong Connect Innovative Drugs ETF

China Biopharmaceutical's Jointly Promoted Drug Shenghetu Approved for First-Line NSCLC Treatment

China Biopharma's Zongertinib Approved by NMPA as First-Line Treatment for HER2-Mutated NSCLC

Hansoh Pharmaceutical's Self-developed Lung Cancer Drug HS-10504 Approved for Breakthrough Therapy Designation

2025 Top 10 Domestic Innovative Drug Companies Revenue Surpasses 100 Billion, BeiGene Leads Turnaround

CSPC PHARMA FY2026 Q1 Earnings Release on May 27 Pre-Market (BJT), Forecast Revenue HKD 7.905 B, EPS HKD 0.102

HKEX Discloses: JPMorgan Increases Short Position in Wuxi AppTec H-Share to 3.34% on May 14

BeiGene 2026 Q1 Earnings Soar: Net Profit Surges 178x, Revenue Breaks 10 Billion RMB Barrier

CSPC's SYH2095 receives clinical trial approval and FDA clearance, trials set to begin in April 2026

BlackRock Increases Stake in Wuxi AppTec H-Shares to 6.32%

China Biopharma spends 10 million HKD to repurchase 1.89 million shares on May 18

BeiGene's Sorotorac Gets FDA Accelerated Approval, Deepening BCL-2 Layout to Mitigate Single-Product Risk

China Biopharma spends 10.0269 million HKD to repurchase 1.87 million shares

Orient Securities: WuXi AppTec 2026 Q1 Net Profit 4.65B, Maintains Buy Rating with Target Price 140.16 Yuan

Zhongtai Securities lowers Sanhome's earnings forecast and maintains Buy rating

BeiGene's Brukinsa Approved by FDA

China Biopharmaceutical Announces Preclinical Results of Obesity Treatment Candidate TQF6422

Hanson Pharma Group Begins HS-10541 Clinical Trial with NMPA Approval

161122

516060

520970

589720

159835

520700

513780

The CSI Innovative Drugs Industry Index surged 11% over the past week. Brokerages believe the innovative drug sector is in a stage of "earnings realization, valuation repair, and conference catalysis." Multiple biopharmaceutical companies have achieved historic turnarounds, with fundamentals improving. In the first quarter of this year, the total amount of China's innovative drug out-licensing reached nearly $57 billion, already exceeding the full-year level of 2024. The upcoming AACR and ASCO annual meetings, with intensive clinical data disclosures, are expected to provide catalysts

Wallstreetcn

E Fund CSI WD Biotechnology Index Fund(LOF)-A

ICBCCS CSI Brand Name Drug Industry ETF

Harvest CSI Hong Kong Connect Innovative Drugs ETF

E Fund CSI Innovative Drugs ETF

J.P.Morgan Asset Management CSI Brand Name Drug Industry ETF

Fullgoal CSI Hugangshen Innovative Drugs Industry ETF

Guotai SSE STAR Brand Name Drug ETF

E Fund Hang Seng SCHK Innovative Drug ETF

CCB Principal CSI Innovative Drugs Industry ETF

Invesco Great Wall CSI Hong Kong Connect Innovative Drug ETF

Eastmoney Fund CSI SH-HK-SZ Brand Name Drug Industry ETF

Guotai CSI Hugangshen Innovative Drugs Industry ETF

Yinhua CSI Innovative Drugs Industry ETF

Innovative Drugs Break Out Again After Six Months, Leading Companies Enter Intensive Harvest Period; Has the Profit Inflection Point Arrived?

02157

The overseas licensing cooperation of innovative pharmaceutical companies continues to be active, and the Harvest CSI Hong Kong Connect Innovative Drugs ETF (520970) is expected to benefit continuously. On the morning of April 1, 2026, the CSI Hong Kong Connect Innovative Drugs Index rose by 4.91%, with constituent stock LEPU BIO-B increasing by 11.24%. In the first three months of 2026, the total value of foreign licensing transactions for innovative drugs in China has exceeded USD 60 billion. The NMPA has launched the "Spring Rain Action" for the transformation of clinical innovation achievements in medical devices, supporting the industrialization of innovative results. The valuation of the pharmaceutical sector is 29.3 times PE, lower than the historical average, and the market's attention to innovative pharmaceutical companies with core technology platforms has increased

腾讯新闻 - 财经

LEPU BIO

Innovative pharmaceutical companies' overseas licensing collaborations remain active, and the Hong Kong Connect Innovative Drugs ETF Harvest (520970) is expected to continue benefiting

520880

513120

159297

520500

On March 27th, the Hong Kong Stock Connect Innovative Drug Index rose by 5.07%. CSPC Pharma increased by over 12%, 3SBIO rose by over 9%, and INNOVENT BIO climbed by over 7%. The Hong Kong Stock Connect Innovative Drug ETF, Harvest (520970), had a trading volume of 126 million yuan and a turnover rate of 12.26%. Several Hong Kong Stock Connect innovative drug targets disclosed their 2025 financial reports, with Hengrui Pharma's innovative drug revenue growing by 26% year-on-year. Zhongyou Securities is optimistic about investment opportunities in the sector, while Morgan Stanley believes that the internationalization of China's innovative drugs is accelerating and is currently in a left-side allocation window

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

INNOVENT BIO

Bosera Hang Seng SCHK Innovative Drug Select ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

HENGRUI PHARMA

CSPC PHARMA

China Southern CNI HK Connect Innovative Drug ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Hengrui Pharma

3SBIO

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

The internationalization of Chinese innovative drugs is accelerating, and the sector is in a left-side allocation window. The Hong Kong Stock Connect Innovative Drug ETF Harvest (520970) is gaining popularity

As of March 9, 2026, the Hong Kong Stock Connect Innovative Drug ETF China Southern (159297) had a turnover of 6.69%, with a transaction volume of 105 million yuan, while the tracked CNI Hong Kong Connect Innovative Drug Index fell by 1.7%. Soochow Securities pointed out that the Two Sessions have for the first time listed innovative drugs as an "emerging pillar industry" and proposed to accelerate the development of commercial insurance to promote the high-quality development of innovative drugs. The biopharmaceutical industry has entered a strategic pillar stage, and the medium- to long-term allocation value of the innovative drug sector has attracted attention, making it a good time for investment

China Southern Fund's Hong Kong Connect Innovative Drug ETF has attracted significant attention from investors, with a concentrated release of favorable news for innovative drugs. Short-term corrections do not change its long-term allocation value

Wanjia CSI Hong Kong Connect Innovative Drugs ETF(520700.SH)

Innovative Drugs Break Out Again After Six Months, Leading Companies Enter Intensive Harvest Period; Has the Profit Inflection Point Arrived?

Innovative pharmaceutical companies' overseas licensing collaborations remain active, and the Hong Kong Connect Innovative Drugs ETF Harvest (520970) is expected to continue benefiting

The internationalization of Chinese innovative drugs is accelerating, and the sector is in a left-side allocation window. The Hong Kong Stock Connect Innovative Drug ETF Harvest (520970) is gaining popularity

China Southern Fund's Hong Kong Connect Innovative Drug ETF has attracted significant attention from investors, with a concentrated release of favorable news for innovative drugs. Short-term corrections do not change its long-term allocation value